Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Moderate Persistent Asthma Clear all
Completed Phase 4 Interventional Results available

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

NCT02794480
View directory record Official record
Conditions
Asthma
Interventions
ELLIPTA DPI, GSK MDI, AZ MDI
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Huntington Beach, California • Aventura, Florida • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 23, 2026, 7:46 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma

NCT01257230
View directory record Official record
Conditions
Asthma
Interventions
tiotropium Respimat low dose, placebo Respimat, tiotropium Respimat high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 17 Years
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Plymouth, Minnesota • Columbia, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 23, 2026, 7:46 PM EDT
Completed Phase 2 Interventional

Study Evaluating Etanercept in Moderate to Severe Asthma

NCT00141791
View directory record Official record
Conditions
Asthma
Interventions
Etanercept
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
13
States / cities
Birmingham, Alabama • Denver, Colorado • Sarasota, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2009 · Synced Oct 23, 2026, 7:46 PM EDT
Completed Phase 3 Interventional

Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid

NCT00174733
View directory record Official record
Conditions
Asthma
Interventions
Ciclesonide (XRP1526)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2009 · Synced Oct 23, 2026, 7:46 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

NCT00267202
View directory record Official record
Conditions
Allergic Asthma
Interventions
Placebo, Omalizumab, Immunotherapy
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 55 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Oct 23, 2026, 7:46 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Expressions of TRPV1 in Airway of Asthmatics

NCT02952066
View directory record Official record
Conditions
Moderate Persistent Asthma, Severe Persistent Asthma, Nodule Solitary Pulmonary, Pulmonary Atelectasis
Interventions
Bronchial biopsy
Procedure
Lead sponsor
Lu Yuan Lee
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 23, 2026, 7:46 PM EDT
Completed Phase 3 Interventional Results available

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

NCT00529529
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol 300 μg, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
56
States / cities
Glendale, Arizona • Phoenix, Arizona • Encinitas, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2011 · Synced Oct 23, 2026, 7:46 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma

NCT01311661
View directory record Official record
Conditions
Asthma
Interventions
Placebo twice daily, Olodaterol low daily dose twice daily, Olodaterol medium daily dose twice daily, Olodaterol high daily dose once daily and placebo, Olodaterol medium daily dose once daily and placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
12
States / cities
Huntington Beach, California • Centennial, Colorado • Wheat Ridge, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Oct 23, 2026, 7:46 PM EDT
Completed Phase 2 Interventional Results available

Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

NCT02433834
View directory record Official record
Conditions
Asthma
Interventions
Glycopyrronium MDI, Serevent Diskus 50 μg, Placebo
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
43
States / cities
Birmingham, Alabama • Anaheim, California • Bakersfield, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 7:46 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma

NCT01122680
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
5
States / cities
Denver, Colorado • Columbia, Missouri • Warrensburg, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 23, 2026, 7:46 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

NCT01172821
View directory record Official record
Conditions
Asthma
Interventions
placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Los Angeles, California • Stockton, California • Centennial, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 23, 2026, 7:46 PM EDT
Completed Phase 2 Interventional

Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation

NCT01581177
View directory record Official record
Conditions
Asthma
Interventions
Albuterol DPI 25 mcg/inh, Albuterol DPI 90 mcg/inh, Placebo DPI, Albuterol MDI 90 mcg/inh
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
4
States / cities
San Jose, California • Medford, Oregon • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 23, 2026, 7:46 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists

NCT00670930
View directory record Official record
Conditions
Allergic Asthma
Interventions
omalizumab at a dose of 0.016mg/kg/IU/mL, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Denver, Colorado • St Louis, Missouri • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 23, 2026, 7:46 PM EDT
Terminated Phase 1 Interventional

Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma

NCT05035862
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Sulfate, Interferon gamma-primed mesenchymal stromal cells (MSCs), Prednisone
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 23, 2026, 7:46 PM EDT
Terminated Phase 2 Interventional Results available

An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma

NCT02219048
View directory record Official record
Conditions
Asthma
Interventions
Placebo, PF-03715455
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 23, 2026, 7:46 PM EDT
Completed Phase 2 Interventional

Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma

NCT00048022
View directory record Official record
Conditions
Asthma
Interventions
Dual Integrin Antagonist
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
59
States / cities
Huntington Beach, California • Los Angeles, California • Mission Viejo, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 23, 2026, 7:46 PM EDT
Completed Phase 2 Interventional

Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation

NCT02210806
View directory record Official record
Conditions
Asthma
Interventions
A006 DPI, Placebo DPI, Proventil® MDI
Drug · Other
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
San Jose, California • Medford, Oregon • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 23, 2026, 7:46 PM EDT
Recruiting No phase listed Observational

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

NCT00576069
View directory record Official record
Conditions
Asthma
Interventions
budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 23, 2026, 7:46 PM EDT
Not yet recruiting Not applicable Interventional

Improving the Quality of Care for Asthma Patients at Risk of Exacerbations

NCT06596512
View directory record Official record
Conditions
Asthma, Asthma Chronic, Asthma Severe Persistent With Exacerbation, Asthma Moderate Persistent With Exacerbation
Interventions
PARTICS using a single ICS add on, MART
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
4,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
New Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 23, 2026, 7:46 PM EDT
Terminated Phase 2 Interventional

Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma

NCT01103037
View directory record Official record
Conditions
Asthma
Interventions
QAV680, QAV680 Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Cypress, California • Charlotte, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 23, 2026, 7:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

TC-6987 for the Treatment of Mild to Moderate Asthma

NCT01296087
View directory record Official record
Conditions
Asthma
Interventions
TC-6987, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
21
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 23, 2026, 7:46 PM EDT
Completed Phase 3 Interventional

Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.

NCT00174720
View directory record Official record
Conditions
Asthma
Interventions
Ciclesonide (XRP1526)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2009 · Synced Oct 23, 2026, 7:46 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma

NCT01634139
View directory record Official record
Conditions
Asthma
Interventions
Tiotropium low dose QD, Tiotropium high dose QD, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 11 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Columbia, Missouri • Cincinnati, Ohio • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 23, 2026, 7:46 PM EDT
Completed Not applicable Interventional

Evaluation of Traditional Paper Symptom Diary vs. the VOCEL Mobile Diary

NCT00367263
View directory record Official record
Conditions
Asthma
Interventions
Alvesco (Ciclesonide) 160 ug/day
Drug
Lead sponsor
Allergy & Asthma Medical Group & Research Center
Other
Eligibility
12 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 2, 2007 · Synced Oct 23, 2026, 7:46 PM EDT